Printed From:

QUESTIONS ABOUT NOVEL CORONAVIRUS?
CLICK HERE.

DUPIXENT is the first biologic to specifically modulate the key immune mechanism in AD by inhibiting IL-4 and IL-13 signalling, key drivers of Type 2 inflammation1,2

DUPIXENT is a target
immunomodulator unlike
broad-spectrum
immunosuppressants1

An injectable biologic, dual inhibitor of IL-4 and IL-13 signalling1,2

What types of moderate-to-severe patients can benefit from DUPIXENT?

  • Patients who are struggling to control their disease with their current treatment1,3–5
  • Patients that do not respond to topical therapies1,3–5

Not an actual patient.

AD, atopic dermatitis; γC, gamma C subunit; IL, interleukin; IL-4Rα, Interleukin 4 receptor alpha; IL-13Rα1, interleukin 13 receptor alpha 1; JAK, Janus kinase; TYK2, tyrosine kinase 2.

References

  1. DUPIXENT Summary of Product Characteristics. September 2021.
  2. Guttman-Yassky E, et al. J Allergy Clin Immunol. 2019;143:155–172.
  3. Blauvelt A, et al. Lancet. 2017;389(10086):2287–2303.
  4. de Bruin-Weller, et al. Clinically Meaningful Responses in Moderate-to-Severe Atopic Dermatitis Patients Treated With Dupilumab presented at the 27th European Academy of Dermatology and Venerology Congress, Paris, France, September 12–16 2018.
  5. Paller AS, et al. Dupilumab for Adolescents With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 3, Randomized, Double-Blinded Trial (Poster 10051) presented at the 77th annual meeting of the American Academy of Dermatology, Washington, DC, USA, March 1–5 2019.